United States Patent 3,783,861: Scope, Claim Construction, Expiration, and IUD Inserter Patent Landscape

U.S. Patent No. 3,783,861 protects a mechanical insertion instrument for flexible intrauterine contraceptive devices, not a drug, active pharmaceutical ingredient, or contraceptive device itself. The patent centers on a tubular inserter that temporarily folds a T-shaped or arm-based intrauterine device, guides it through a barrel, controls insertion depth at the cervical os, and deploys it in the uterine cavity.

The patent issued on January 8, 1974. Because it is a pre-June 8, 1995 U.S. patent, its ordinary term was 17 years from grant under the law then in effect. Absent an unusual terminal disclaimer or other case-specific adjustment, the patent expired on January 8, 1991. It therefore presents no current U.S. patent barrier to manufacture, sale, or use of an otherwise lawful IUD inserter.

What technology does U.S. Patent 3,783,861 protect?

The patent protects an insertion instrument with five principal technical functions:

Temporary accommodation of a flexible intrauterine contraceptive device inside a tubular barrel.
Folding of one transverse arm so the device can pass through the barrel.
Axial propulsion of the folded device by a plunger.
Control of insertion depth through a stop engaging the cervical os.
Release of the device at a predetermined uterine location.

The claims focus on the instrument architecture and deployment sequence. They do not claim:

A pharmaceutical composition.
A hormone, copper, or other active contraceptive substance.
The structural design of the IUD as an independent article.
A method of contraception as such.
A manufacturing process for an IUD.
A specific drug-eluting intrauterine system.

The patent is therefore best classified as a historical medical-device patent covering IUD delivery equipment.

How many independent claims does Patent 3,783,861 contain?

The supplied claims identify three apparent independent claim groups: claims 1, 17, and 26.

Claim	Apparent status	Core subject matter
1	Independent apparatus claim	Barrel, cervical stop, opposed apertures, folding mechanism, and plunger
17	Independent apparatus claim	Barrel, opposed apertures, folding mechanism, and plunger for a device with an arcuate second arm
26	Independent apparatus claim	Barrel, grooved stop, longitudinal slot, auxiliary plunger stop, and rearward withdrawal of the barrel

Claims 2 through 16 generally depend from claim 1. Claims 18 through 25 appear intended to depend from claim 17, although the supplied text contains inconsistent cross-references. Claim 27 appears intended to depend from claim 26.

The claim dependencies should be checked against the certified patent document before relying on the text in litigation, freedom-to-operate work, or a chain-of-title analysis. The supplied wording includes apparent errors, including references to claims 20, 21, 23, 26, and 27 in places where the dependency structure would otherwise be expected to refer to claim 17 or another preceding claim.

What elements are required by claim 1?

Claim 1 is the broadest and most commercially significant claim in the first claim group. A practicing device would need to satisfy each of the following limitations:

Claim 1 limitation	Technical meaning
Flexible contraceptive device	The instrument is designed for a flexible IUD having a first transverse arm and a second dependent arm
Tubular barrel	The delivery instrument has a hollow barrel
Insertion end	The barrel has a forward end intended for uterine insertion
Stop means	A structure engages the cervical os
Predetermined insertion depth	The stop is positioned relative to the barrel’s anterior end to control penetration
Diametrically opposed axial apertures	The barrel has opposing longitudinal openings
Device reception through apertures	The first arm extends transversely through the openings
Second arm inside the barrel	The dependent arm extends through one aperture and axially into the barrel
Folding means	A structure folds the transverse arm into the barrel beside the second arm
Plunger	A telescoping member engages the second arm
Deployment movement	The plunger advances the folded device through the insertion end
Predetermined uterine deposition	The device is deposited at a selected uterine location

A competitor would not avoid claim 1 merely by changing the IUD material, adding radiopaque markers, or using a different contraceptive material. The claim is directed primarily to the mechanical relationship between the device, apertures, folding structure, barrel, stop, and plunger.

A design that uses a completely different loading path, such as loading the IUD entirely through the rear of the barrel without opposed lateral apertures, would present a stronger non-infringement position. A delivery system using a sheath, retractable outer tube, or pre-folded device could also avoid one or more express limitations, depending on its construction.

What additional features are protected by claims 2 through 16?

The dependent claims narrow the first claim group through specific mechanical features.

Crossbar folding mechanism

Claim 2 adds a pivoting crossbar that rotates from a transverse position to an axial position. Two depending abutments engage opposite portions of the transverse arm and force it into the barrel.

Claims 3 and 4 add a locking arrangement that holds the crossbar in the aligned position against the bias of the flexible arm. Claim 4 specifies cooperating protuberances on the barrel and crossbar.

These claims are narrower than claim 1 because they require a particular folding structure rather than any mechanism that performs the folding function.

Plunger and operator features

Claim 5 requires a finger-press portion on the rear of the plunger. Claim 6 requires a generally cruciform plunger cross-section. Claim 7 adds a thumb rest on the barrel.

These elements are ergonomic and structural limitations. They would not cover an otherwise equivalent inserter lacking the claimed cruciform plunger or thumb rest.

Curved insertion end

Claim 8 requires a curved insertion end that generally conforms to the uterine cavity. Claim 9 adds a thumb rest positioned on the side corresponding to the curve, allowing the operator to identify the orientation of the tip.

A straight inserter may avoid claims 8 and 9, but it could still fall within claim 1 if all claim 1 limitations are present.

Adjustable insertion-depth stop

Claims 10 through 13 cover a removable stop that can be positioned at different distances from the insertion end.

The claims identify:

Multiple recesses along the barrel.
Frictional engagement between the stop and selected recesses.
A semi-cylindrical stop body.
A flange engaging generally annular recesses.
An axial length that protects surrounding tissue when the stop is placed at the most posterior position.

These claims protect adjustability and stop geometry rather than a fixed-depth delivery instrument.

Auxiliary stop and barrel-withdrawal deployment

Claim 14 adds a longitudinal slot extending along substantially the entire barrel. An auxiliary stop on the plunger travels through the slot and engages the cervical os. Continued plunger movement causes the barrel to move rearward relative to the plunger, freeing the IUD.

Claims 15 and 16 add rear fingerpieces and the crossbar folding mechanism.

This is a distinct deployment concept. Instead of simply pushing the IUD out of the forward end, the plunger and barrel move relative to each other after the auxiliary stop reaches the cervical os.

What is covered by claims 17 through 25?

Claim 17 is a second broad apparatus claim directed to an IUD having a first transverse arm and a second arcuate arm dependent from one end of the first arm.

Compared with claim 1, claim 17 appears to omit the cervical-os stop limitation. It retains:

A tubular barrel.
Diametrically opposed axial apertures.
A transverse arm extending through the apertures.
A second arm extending into the barrel.
A folding mechanism.
A plunger engaging the device.
Deployment through the insertion end.

This broader structure may have been intended to capture the core loading and deployment arrangement even where the instrument did not include the specific depth-stop arrangement recited in claim 1.

The later claims add:

A pivoting crossbar.
Abutments positioned to engage the arm connection.
A recess accommodating the arm junction.
An extension entering the adjacent aperture.
An inclined surface guiding the junction into the barrel.
A locking mechanism.
A cruciform plunger.
A curved insertion tip.
A thumb rest.
A reduced-diameter insertion end.

The arm-junction guide in claim 19 is technically important. It addresses the risk that the connection between the transverse and arcuate arms could catch on the barrel aperture during deployment.

What does claim 26 protect?

Claim 26 is a separate instrument claim directed to an IUD inserter having:

A tubular barrel.
An insertion end.
A stop with a groove.
An axial barrel slot aligned with the stop groove.
A telescoping plunger.
An auxiliary stop member at the anterior end of the plunger.
Relative rearward movement of the barrel after the auxiliary stop engages the cervical os.

The claim does not expressly require the opposed apertures or crossbar folding structure found in claims 1 and 17. Its principal innovation is the coordinated slot-and-groove arrangement that permits the auxiliary plunger stop to engage the cervical os while the barrel retracts.

Claim 27 adds oppositely extending fingerpieces on the barrel.

A modern inserter using a fixed external flange, a retractable sheath, or a different deployment sequence would likely require separate analysis against claim 26. The absence of a crossbar limitation makes claim 26 structurally distinct from the folding claims.

When did U.S. Patent 3,783,861 lose exclusivity?

Event	Date or status
Patent issued	January 8, 1974
Ordinary pre-1995 patent term	17 years from issue
Expected ordinary expiration	January 8, 1991
Current enforceability	Expired
Current infringement risk	No enforceable U.S. patent rights under this patent

The governing term rule for patents issued before June 8, 1995 generally provided 17 years from grant, subject to statutory exceptions. The Uruguay Round Agreements Act changed the standard term for later patents to 20 years from the earliest effective nonprovisional filing date, but that regime does not revive or extend this patent’s ordinary term. [1]

No patent-term-extension analysis is relevant because the patent claims a medical instrument rather than a regulated drug product. Drug patent term restoration under 35 U.S.C. § 156 does not ordinarily apply to this type of device patent.

What is the Orange Book status of Patent 3,783,861?

Patent 3,783,861 is not an Orange Book drug patent.

The FDA Orange Book lists patents and exclusivity information associated with approved drug products submitted under applicable new drug application pathways. A mechanical IUD inserter is not an active ingredient, drug formulation, method of treatment, or drug delivery patent listed against an NDA in the ordinary Orange Book framework. [2]

The patent therefore does not create:

An Orange Book-listed patent barrier.
A Paragraph IV certification issue.
An ANDA litigation trigger.
Small-molecule generic-delay exposure.
FDA drug exclusivity.

The distinction matters commercially. A product may combine a drug or hormone with a delivery system, but the patent status of the inserter and the patent status of the drug-device product must be analyzed separately.

Are Paragraph IV challenges or biosimilar risks relevant?

No direct Paragraph IV or biosimilar issue arises from Patent 3,783,861.

Paragraph IV litigation concerns patents listed for approved drugs in the Orange Book. Biosimilar litigation concerns biologic products and patents typically addressed through the Biologics Price Competition and Innovation Act framework. An expired mechanical inserter patent falls outside both pathways.

For levonorgestrel-releasing IUDs, the relevant competitive questions may instead involve:

FDA approval of the drug-device combination.
Device classification and premarket review.
Product-specific patents covering the reservoir, polymer matrix, release profile, or manufacturing process.
Brand or generic drug-device regulatory pathways.
Trade dress, design, and manufacturing know-how.

Those rights are separate from the expired patent analyzed here.

What is the patent landscape for IUD insertion instruments?

The historical landscape can be divided into four technology groups.

Technology group	Typical protection focus	Relationship to Patent 3,783,861
Flexible arm-based IUD inserters	Folding transverse arms into a barrel	Directly addressed
Copper IUD delivery systems	Loading, release, and device-specific insertion geometry	May overlap functionally but requires separate claim analysis
Hormonal IUD inserters	Reservoir protection, sheath deployment, insertion depth, and release	Generally distinct product-specific estates
Modern single-use applicators	Retractable sleeves, strings, release buttons, and preloaded devices	May avoid the claimed opposed-aperture and crossbar architecture

Historical products such as Lippes Loop, Copper-7, and other flexible IUD designs used insertion systems with different mechanical arrangements. Current hormonal and copper IUD products generally use product-specific delivery systems. Their patent estates are more likely to concern the IUD structure, drug reservoir, polymer composition, manufacturing process, release profile, or applicator configuration than the exact 1970s crossbar architecture.

The existence of functional similarity does not establish infringement. Patent 3,783,861 requires the particular combinations recited in its claims, and the patent is expired in any event.

What manufacturing and intellectual-property barriers remain?

Patent 3,783,861 does not present a current manufacturing barrier in the United States. The principal remaining barriers for an IUD inserter are regulatory and quality-system requirements.

A manufacturer may still need to address:

FDA device classification and premarket requirements.
Biocompatibility of patient-contacting materials.
Sterilization validation.
Packaging and shelf-life validation.
Mechanical performance and deployment reliability.
Human-factors engineering.
Manufacturing controls under the FDA Quality System Regulation.
Product-specific patents owned by current IUD manufacturers.
Confidential manufacturing know-how and supplier qualification.

The expired patent may remain relevant as prior art. Its drawings and claim concepts can support an obviousness or novelty analysis against later patent applications, especially those claiming folding arm inserters, cervical depth stops, barrel retraction, or plunger-guided deployment.

Which companies are challenging Patent 3,783,861?

No current challenge is necessary because the patent has expired. Paragraph IV challengers, post-grant review petitioners, and inter partes review petitioners do not have a practical role against an expired 1974 patent.

A historical assignment or licensing review would require the USPTO assignment records and any litigation docket associated with the patent. The claim text alone does not establish a licensing deal, settlement agreement, enforcement action, or ownership history. There is no basis in the supplied material to attribute a current license, settlement, or litigation disposition to a particular company.

How strong is the patent estate for this technology?

As an enforceable estate, it has no current U.S. strength because the patent expired more than three decades ago.

As prior art, it remains technically significant in four areas:

Folding a flexible IUD for passage through a tubular inserter.
Using opposed barrel apertures to receive device arms.
Controlling insertion depth with a cervical-os stop.
Deploying the device through relative plunger and barrel movement.

The estate’s historical strength came from its combination claims. The broadest claims did not merely recite an IUD applicator; they required a specific interaction among the IUD geometry, barrel apertures, folding structure, plunger, and uterine deployment sequence.

What generic launch risks exist?

There is no generic launch risk from Patent 3,783,861 itself. A manufacturer can use the disclosed concepts without facing infringement liability under an expired patent.

Commercial launch risk may still arise from separate rights covering:

A branded copper IUD.
A levonorgestrel-releasing IUD.
The active pharmaceutical ingredient or dosage form.
The drug reservoir or polymer matrix.
The release-rate profile.
A current applicator design.
Manufacturing methods.
Regulatory exclusivity.
Trademarks and product configuration.

The appropriate freedom-to-operate conclusion is therefore narrow: this patent is expired and cannot independently block a new U.S. IUD inserter, but it should be included in prior-art and patentability searches for later applicator patents.

Key Takeaways

U.S. Patent 3,783,861 is a medical-device patent, not a drug patent.
It covers mechanical insertion instruments for flexible intrauterine contraceptive devices.
The principal claim groups are claims 1, 17, and 26.
The core limitations include a tubular barrel, arm-receiving apertures, a folding mechanism, a plunger, and controlled uterine deployment.
Claims 10 through 13 cover adjustable insertion-depth stops.
Claims 14 through 16 and 26 through 27 cover auxiliary-stop and barrel-retraction deployment concepts.
The patent issued January 8, 1974 and ordinarily expired January 8, 1991.
It has no current Orange Book, Paragraph IV, or biosimilar significance.
It creates no current U.S. infringement barrier.
It remains relevant as prior art against later IUD applicator patents.
The supplied claim text contains apparent dependency and numbering defects that should be verified against the certified patent document before legal reliance.

FAQs

Does Patent 3,783,861 cover the IUD itself?

No. The claims cover an instrument for inserting a flexible IUD. They do not independently claim the contraceptive device, copper structure, hormone reservoir, or drug formulation.

Can a company manufacture an IUD inserter based on this patent?

Yes, the patent’s U.S. rights have expired. Separate patents covering a later commercial IUD, applicator design, manufacturing process, or drug-device combination may still require review.

Is Patent 3,783,861 listed in the FDA Orange Book?

No. It is a device patent and does not ordinarily qualify as an Orange Book-listed drug patent.

Does the patent affect generic Mirena, Kyleena, Liletta, or Paragard entry?

Not directly. Generic or follow-on entry for those products depends on separate drug-device patents, FDA requirements, product-specific exclusivity, and other intellectual-property rights.

Can the patent be used as prior art against a new IUD applicator patent?

Yes. Its disclosure may be relevant to novelty and obviousness analyses involving folding IUD arms, barrel-based delivery, cervical depth stops, auxiliary plunger stops, and relative barrel-plunger movement.

References

United States Patent and Trademark Office. (n.d.). Patent term and adjustment information. U.S. Department of Commerce.
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.
United States Patent and Trademark Office. (1974). U.S. Patent No. 3,783,861: Insertion instrument for intrauterine contraceptive device.
35 U.S.C. §§ 154, 156.
21 C.F.R. Part 4. Regulation of combination products.

Details for Patent: 3,783,861

Summary for Patent: 3,783,861